EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mechanism exploration of galangin against non-small cell lung cancer based on network pharmacology, molecular docking, and experimental validation

Yanping Liu, Shaochu Zheng, Haizhu Huang, Jiahui Han, Jinliang Kong

Discover Oncology · 18.11.2026

DOI: 10.1007/s12672-026-06322-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 18.11.2026. Verfasst von Yanping Liu und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Key Research Program of Guangxi Science and Technology Department.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Galangin is a natural flavonoid with reported anticancer effects, but how it acts in non-small cell lung cancer (NSCLC) is not fully understood. This study explored its potential targets and effects on NSCLC cells. We combined network pharmacology, molecular docking, 100-ns molecular dynamics simulations, and in vitro experiments. We identified 101 overlapping targets of galangin and NSCLC. Protein–protein interaction analysis highlighted six hub genes: AKT1 , STAT3 , MYC , HIF1A , CASP3 , and IL6 . Among the enriched pathways, PI3K/AKT signaling ranked highest. Molecular docking predicted favorable interactions between galangin and all six hub proteins, while molecular dynamics simulations suggested stability of the galangin–AKT1 complex. In vitro experiments showed that galangin reduced the proliferation, migration, and invasion of A549 and H1299 cells. It also decreased p-PI3K and p-AKT levels, with little change in total PI3K and AKT levels. 740Y-P partially reversed galangin-induced inhibition of migration and invasion and restored p-PI3K/p-AKT levels. Galangin inhibits the proliferation, migration, and invasion of NSCLC cells, at least in part by inhibiting PI3K/AKT signaling. This work provides a mechanistic basis for developing galangin as a potential therapeutic solution for NSCLC.

Förderung

  • The Key Research Program of Guangxi Science and Technology Department

Zitieren

APA

Liu, Y., Zheng, S., Huang, H., Han, J., & Kong, J. (2026). Mechanism exploration of galangin against non-small cell lung cancer based on network pharmacology, molecular docking, and experimental validation. Discover Oncology. https://doi.org/10.1007/s12672-026-06322-0

Vancouver

Liu Y, Zheng S, Huang H, Han J, Kong J. Mechanism exploration of galangin against non-small cell lung cancer based on network pharmacology, molecular docking, and experimental validation. Discover Oncology. 2026. doi:10.1007/s12672-026-06322-0

BibTeX
@article{Liu2026,
  author = {Liu, Yanping and Zheng, Shaochu and Huang, Haizhu and Han, Jiahui and Kong, Jinliang},
  title = {Mechanism exploration of galangin against non-small cell lung cancer based on network pharmacology, molecular docking, and experimental validation},
  journal = {Discover Oncology},
  year = {2026},
  doi = {10.1007/s12672-026-06322-0}
}
Kostenlos starten →